PFDN6 is a subunit of the prefoldin complex that functions as a co-chaperone, assisting in protein folding by binding to nascent polypeptide chains and transferring target proteins to cytosolic chaperonin complexes 1. The protein plays critical roles in maintaining cellular protein homeostasis and epithelial integrity, as demonstrated in mosquito studies where PFDN6 silencing compromised extracellular matrix integrity and triggered immune responses 1. In cancer contexts, PFDN6 exhibits oncogenic properties, with overexpression correlating with poor prognosis in gastric cancer patients, particularly in HER2+ and diffuse-type subsets 2. In gliomas, PFDN6 promotes tumor progression through AKT signaling pathway activation, enhancing cell proliferation and migration while inhibiting apoptosis 3. The protein has also been identified as a biomarker in various disease contexts, including osteoporosis risk prediction 4, ovarian cancer prognosis 5, nonalcoholic fatty liver disease 6, and COVID-19 susceptibility in lung adenocarcinoma patients 7. These findings suggest PFDN6 functions beyond basic protein folding, influencing disease pathogenesis through multiple molecular pathways and representing a potential therapeutic target across diverse pathological conditions.